TapewireFind a company

person · Reporting owner

Afeyan Noubar

Disclosed activity across 17 companies

Tapewire entity
44731
SEC CIK
0001222012

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Axcella Health Inc.AXLA · Entity 11605910% ownerOctober 13, 2022October 17, 2022
Codiak BioSciences, Inc.CDAK · Entity 11495810% ownerSeptember 15, 2022September 16, 2022
Evelo Biosciences, Inc.EVLO · Entity 10846810% ownerJuly 11, 2023July 13, 2023
Foghorn Therapeutics Inc.FHTX · Entity 5820Director · 10% ownerJanuary 13, 2026January 15, 2026
Generate Biomedicines, Inc.GENB · Entity 1553Director · 10% ownerFebruary 26, 2026March 02, 2026
Kaleido Biosciences, Inc.KLDO · Entity 12974510% ownerFebruary 08, 2021February 10, 2021
Moderna, Inc.MRNA · Entity 2025DirectorMay 21, 2026May 22, 2026
Omega Therapeutics, Inc.OMGA · Entity 83618Director · 10% ownerJune 07, 2023June 09, 2023
Rubius Therapeutics, Inc.RUBY · Entity 116417Director · 10% ownerMay 12, 2022May 13, 2022
Sana Biotechnology, Inc.SANA · Entity 487010% ownerFebruary 12, 2024February 14, 2024
Seres Therapeutics, Inc.MCRB · Entity 719110% ownerJuly 05, 2022July 07, 2022
Syros Pharmaceuticals, Inc.SYRS · Entity 8543710% ownerDecember 31, 2017February 13, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Flagship Ventures Fund IV, L.P.14,101,638 Last balance in matching sequence After 2022-10-13 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2022-10-13 · Purchase · Acquired 2,743,902 · Balance 11,344,305

F1: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022.

F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Row 2 · 2022-10-13 · Purchase · Acquired 2,757,333 · Balance 14,101,638

F3: Represents shares of Common Stock issued upon conversion of unsecured convertible promissory notes (the "Notes") previously held by Flagship Fund IV and Flagship Opportunities I that were issued pursuant to the terms of the Securities Purchase Agreement dated September 20, 2022. In connection with the October 2022 Offering, the conversion price of the Notes became fixed at $1.64 and the outstanding principal plus accrued interest of the Notes held by Flagship Fund IV and Flagship Opportunities I automatically converted into 2,757,333 shares and 919,111 shares, respectively, of the Issuer's Common Stock.

F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship Ventures Opportunities I, L.P.6,299,611 Last balance in matching sequence After 2022-10-13 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 3 · 2022-10-13 · Purchase · Acquired 914,634 · Balance 5,380,500

F1: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022.

F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

Row 4 · 2022-10-13 · Purchase · Acquired 919,111 · Balance 6,299,611

F3: Represents shares of Common Stock issued upon conversion of unsecured convertible promissory notes (the "Notes") previously held by Flagship Fund IV and Flagship Opportunities I that were issued pursuant to the terms of the Securities Purchase Agreement dated September 20, 2022. In connection with the October 2022 Offering, the conversion price of the Notes became fixed at $1.64 and the outstanding principal plus accrued interest of the Notes held by Flagship Fund IV and Flagship Opportunities I automatically converted into 2,757,333 shares and 919,111 shares, respectively, of the Issuer's Common Stock.

F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy FPA, L.P.3,048,780 Reported balance After 2022-10-13 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 5 · 2022-10-13 · Purchase · Acquired 3,048,780 · Balance 3,048,780

F1: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022.

F5: Shares held by FPA Fund. FPA General Partner LLC ("FPA Fund GP") is the general partner of FPA Fund. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of FPA Fund GP. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except for FPA Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship Ventures Fund IV-Rx, L.P.2,004,657 Reported balance Holding disclosure · report date 2022-10-13 · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · Balance 2,004,657

F6: Shares held by Flagship Ventures Fund IV-Rx, L.P., ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship VentureLabs IV, LLC2,035,830 Reported balance Holding disclosure · report date 2022-10-13 · row 7 Holding and transaction disclosures are not merged.
1 source row

Row 7 · Balance 2,035,830

F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship Ventures Fund 2007, L.P.1,761,029 Reported balance Holding disclosure · report date 2022-10-13 · row 8 Holding and transaction disclosures are not merged.
1 source row

Row 8 · Balance 1,761,029

F8: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures Fund 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022.

F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F3: Represents shares of Common Stock issued upon conversion of unsecured convertible promissory notes (the "Notes") previously held by Flagship Fund IV and Flagship Opportunities I that were issued pursuant to the terms of the Securities Purchase Agreement dated September 20, 2022. In connection with the October 2022 Offering, the conversion price of the Notes became fixed at $1.64 and the outstanding principal plus accrued interest of the Notes held by Flagship Fund IV and Flagship Opportunities I automatically converted into 2,757,333 shares and 919,111 shares, respectively, of the Issuer's Common Stock.

F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

F5: Shares held by FPA Fund. FPA General Partner LLC ("FPA Fund GP") is the general partner of FPA Fund. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of FPA Fund GP. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except for FPA Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F6: Shares held by Flagship Ventures Fund IV-Rx, L.P., ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F8: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures Fund 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Flagship Ventures Fund V, L.P.1,865,767 Reported balance After 2022-09-15 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2022-09-15 · Purchase · Acquired 722,590 · Balance 1,865,767

F1: On September 15, 2022, pursuant to an underwritten public offering by the Issuer (the "Offering"), Flagship Ventures Fund V, L.P. ("Flagship Fund V") acquired 722,590 shares of Common Stock and accompanying warrants to purchase 722,590 shares of Common Stock, and Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx") acquired 210,743 shares of Common Stock and accompanying warrants to purchase 210,743 shares of Common Stock. The combined purchase price in the Offering was $1.50 per share of Common Stock and accompanying warrant.

F2: Shares held by Flagship Fund V. Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship V VentureLabs Rx Fund, L.P.1,188,920 Reported balance After 2022-09-15 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2022-09-15 · Purchase · Acquired 210,743 · Balance 1,188,920

F1: On September 15, 2022, pursuant to an underwritten public offering by the Issuer (the "Offering"), Flagship Ventures Fund V, L.P. ("Flagship Fund V") acquired 722,590 shares of Common Stock and accompanying warrants to purchase 722,590 shares of Common Stock, and Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx") acquired 210,743 shares of Common Stock and accompanying warrants to purchase 210,743 shares of Common Stock. The combined purchase price in the Offering was $1.50 per share of Common Stock and accompanying warrant.

F3: Shares held by Flagship Fund V Rx. Flagship V GP is the general partner of Flagship Fund V Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except for Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2027-09-15IndirectBy Flagship Ventures Fund V, L.P.722,590 Reported balance After 2022-09-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2022-09-15 · Purchase · Acquired 722,590 · Balance 722,590

F1: On September 15, 2022, pursuant to an underwritten public offering by the Issuer (the "Offering"), Flagship Ventures Fund V, L.P. ("Flagship Fund V") acquired 722,590 shares of Common Stock and accompanying warrants to purchase 722,590 shares of Common Stock, and Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx") acquired 210,743 shares of Common Stock and accompanying warrants to purchase 210,743 shares of Common Stock. The combined purchase price in the Offering was $1.50 per share of Common Stock and accompanying warrant.

F2: Shares held by Flagship Fund V. Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2027-09-15IndirectBy Flagship V VentureLabs Rx Fund, L.P.210,743 Reported balance After 2022-09-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2022-09-15 · Purchase · Acquired 210,743 · Balance 210,743

F1: On September 15, 2022, pursuant to an underwritten public offering by the Issuer (the "Offering"), Flagship Ventures Fund V, L.P. ("Flagship Fund V") acquired 722,590 shares of Common Stock and accompanying warrants to purchase 722,590 shares of Common Stock, and Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx") acquired 210,743 shares of Common Stock and accompanying warrants to purchase 210,743 shares of Common Stock. The combined purchase price in the Offering was $1.50 per share of Common Stock and accompanying warrant.

F3: Shares held by Flagship Fund V Rx. Flagship V GP is the general partner of Flagship Fund V Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except for Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectFlagship VentureLabs V LLC485,949 Reported balance Holding disclosure · report date 2022-09-15 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 485,949

F4: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On September 15, 2022, pursuant to an underwritten public offering by the Issuer (the "Offering"), Flagship Ventures Fund V, L.P. ("Flagship Fund V") acquired 722,590 shares of Common Stock and accompanying warrants to purchase 722,590 shares of Common Stock, and Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx") acquired 210,743 shares of Common Stock and accompanying warrants to purchase 210,743 shares of Common Stock. The combined purchase price in the Offering was $1.50 per share of Common Stock and accompanying warrant.

F2: Shares held by Flagship Fund V. Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F3: Shares held by Flagship Fund V Rx. Flagship V GP is the general partner of Flagship Fund V Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except for Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F4: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Flagship Ventures Fund IV, L.P.1,461,795 Reported balance After 2023-07-11 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2023-07-11 · Purchase · Acquired 1,082,251 · Balance 1,461,795

F1: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share.

F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Nutritional Health LTP Fund, L.P.1,493,241 Reported balance After 2023-07-11 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2023-07-11 · Purchase · Acquired 1,082,251 · Balance 1,493,241

F1: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share.

F3: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Nutritional LTP GP. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship Pioneering Fund VII, L.P.3,931,685 Reported balance After 2023-07-11 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2023-07-11 · Purchase · Acquired 3,246,753 · Balance 3,931,685

F1: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share.

F4: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the reporting persons except for Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship Ventures Fund IV-Rx, L.P.94,371 Reported balance Holding disclosure · report date 2023-07-11 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 94,371

F5: Shares held by Flagship Ventures Fund IV-Rx, L.P ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship Ventures Opportunities Fund I, L.P.274,766 Reported balance Holding disclosure · report date 2023-07-11 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 274,766

F6: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship VentureLabs IV LLC34,219 Reported balance Holding disclosure · report date 2023-07-11 · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · Balance 34,219

F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is the manager of VentureLabs IV. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship VentureLabs V LLC132,282 Reported balance Holding disclosure · report date 2023-07-11 · row 7 Holding and transaction disclosures are not merged.
1 source row

Row 7 · Balance 132,282

F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering is the manager of VentureLabs V Manager. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship Ventures Fund V, L.P.210,064 Reported balance Holding disclosure · report date 2023-07-11 · row 8 Holding and transaction disclosures are not merged.
1 source row

Row 8 · Balance 210,064

F9: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship V VentureLabs Rx Fund, L.P.80,494 Reported balance Holding disclosure · report date 2023-07-11 · row 9 Holding and transaction disclosures are not merged.
1 source row

Row 9 · Balance 80,494

F10: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Each of the reporting persons except for VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Nutritional Health Side Fund, L.P.39,798 Reported balance Holding disclosure · report date 2023-07-11 · row 10 Holding and transaction disclosures are not merged.
1 source row

Row 10 · Balance 39,798

F11: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Nutritional Health Disruptive Innovation Fund, L.P.179,909 Reported balance Holding disclosure · report date 2023-07-11 · row 11 Holding and transaction disclosures are not merged.
1 source row

Row 11 · Balance 179,909

F12: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share.

F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F3: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Nutritional LTP GP. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F4: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the reporting persons except for Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F5: Shares held by Flagship Ventures Fund IV-Rx, L.P ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F6: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is the manager of VentureLabs IV. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering is the manager of VentureLabs V Manager. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F9: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F10: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Each of the reporting persons except for VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F11: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F12: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Pre-Funded Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2046-01-13IndirectBy Flagship Pioneering Fund VII, L.P.2,235,468 Reported balance After 2026-01-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-01-13 · Grant · Acquired 2,235,468 · Balance 2,235,468

F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants.

F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Series 1 Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $13.42 · Expires 2027-06-30IndirectBy Flagship Pioneering Fund VII, L.P.1,117,734 Reported balance After 2026-01-13 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-01-13 · Grant · Acquired 1,117,734 · Balance 1,117,734

F3: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism.

F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants.

F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Series 2 Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $20.13 · Expires 2030-12-31IndirectBy Flagship Pioneering Fund VII, L.P.1,117,734 Reported balance After 2026-01-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-01-13 · Grant · Acquired 1,117,734 · Balance 1,117,734

F3: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism.

F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants.

F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants.

F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F3: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Flagship Pioneering Fund VI, L.P.12,723,940 Reported balance After 2026-03-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2026-03-02 · Conversion · Acquired 12,723,940 · Balance 12,723,940

F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F2: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date.

Common StockSEC Table I · non-derivativeIndirectBy Flagship Pioneering Fund VII, L.P.15,264,724 Last balance in matching sequence After 2026-03-02 transaction · row 6 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 2 · 2026-03-02 · Conversion · Acquired 13,702,224 · Balance 13,702,224

F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Row 6 · 2026-03-02 · Purchase · Acquired 1,562,500 · Balance 15,264,724

F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectBy Nutritional Health LTP Fund, L.P.987,491 Reported balance After 2026-03-02 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2026-03-02 · Conversion · Acquired 987,491 · Balance 987,491

F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F4: Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectBy Flagship Pioneering Special Opportunities Fund II, L.P.2,777,752 Reported balance After 2026-03-02 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 4 · 2026-03-02 · Conversion · Acquired 2,777,752 · Balance 2,777,752

F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F5: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectBy FPN II, L.P.4,340,252 Last balance in matching sequence After 2026-03-02 transaction · row 7 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 5 · 2026-03-02 · Conversion · Acquired 2,777,752 · Balance 2,777,752

F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Row 7 · 2026-03-02 · Purchase · Acquired 1,562,500 · Balance 4,340,252

F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectBy Pioneering Medicines 02, LLC1,562,500 Reported balance After 2026-03-02 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 8 · 2026-03-02 · Purchase · Acquired 1,562,500 · Balance 1,562,500

F7: Securities held by Pioneering Medicine 02, LLC ("PM02"). Charles R. Carelli, Jr., Chief Financial Officer of Flagship Pioneering, is the sole manager of PM02, and Flagship Fund VII is its majority equity holder. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-02-25Direct29,561 Reported balance After 2026-02-26 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2026-02-26 · Grant · Acquired 29,561 · Balance 29,561

F9: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

Series A Preferred StockSEC Table II · derivative / convertible securityIndirectBy Flagship Pioneering Fund VI, L.P.0 Reported balance After 2026-03-02 transaction · row 11 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 11 · 2026-03-02 · Conversion · Disposed 18,483,785 · Balance 0

F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F2: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date.

Series A Preferred StockSEC Table II · derivative / convertible securityIndirectBy Flagship Pioneering Fund VII, L.P.0 Reported balance After 2026-03-02 transaction · row 12 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 12 · 2026-03-02 · Conversion · Disposed 17,016,215 · Balance 0

F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Series A Preferred StockSEC Table II · derivative / convertible securityIndirectBy Nutritional Health LTP Fund, L.P.0 Reported balance After 2026-03-02 transaction · row 13 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 13 · 2026-03-02 · Conversion · Disposed 1,500,000 · Balance 0

F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F4: Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectBy Flagship Pioneering Fund VI, L.P.0 Reported balance After 2026-03-02 transaction · row 14 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 14 · 2026-03-02 · Conversion · Disposed 843,881 · Balance 0

F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F2: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectBy Flagship Pioneering Fund VII, L.P.0 Reported balance After 2026-03-02 transaction · row 15 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 15 · 2026-03-02 · Conversion · Disposed 1,265,822 · Balance 0

F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectBy Flagship Pioneering Special Opportunities Fund II, L.P.0 Reported balance After 2026-03-02 transaction · row 16 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 16 · 2026-03-02 · Conversion · Disposed 2,953,586 · Balance 0

F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F5: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectBy FPN II, L.P.0 Reported balance After 2026-03-02 transaction · row 17 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 17 · 2026-03-02 · Conversion · Disposed 2,109,704 · Balance 0

F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Series C Preferred StockSEC Table II · derivative / convertible securityIndirectBy Flagship Pioneering Fund VII, L.P.0 Reported balance After 2026-03-02 transaction · row 18 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 18 · 2026-03-02 · Conversion · Disposed 2,531,644 · Balance 0

F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Series C Preferred StockSEC Table II · derivative / convertible securityIndirectBy Flagship Pioneering Special Opportunities Fund II, L.P.0 Reported balance After 2026-03-02 transaction · row 19 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 19 · 2026-03-02 · Conversion · Disposed 1,265,822 · Balance 0

F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F5: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Series C Preferred StockSEC Table II · derivative / convertible securityIndirectBy FPN II, L.P.0 Reported balance After 2026-03-02 transaction · row 20 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 20 · 2026-03-02 · Conversion · Disposed 2,109,704 · Balance 0

F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectBy Flagship VentureLabs VI, LLC25,016,458 Reported balance Holding disclosure · report date 2026-02-26 · row 9 Holding and transaction disclosures are not merged.
1 source row

Row 9 · Balance 25,016,458

F8: Securities held by Flagship VentureLabs VI LLC ("VentureLabs VI"). Flagship VentureLabs VI Manager LLC ("VentureLabs VI Manager") is the manager of VentureLabs VI. Flagship Pioneering is the manager of VentureLabs VI Manager. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F2: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date.

F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F4: Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F5: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F7: Securities held by Pioneering Medicine 02, LLC ("PM02"). Charles R. Carelli, Jr., Chief Financial Officer of Flagship Pioneering, is the sole manager of PM02, and Flagship Fund VII is its majority equity holder. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F8: Securities held by Flagship VentureLabs VI LLC ("VentureLabs VI"). Flagship VentureLabs VI Manager LLC ("VentureLabs VI Manager") is the manager of VentureLabs VI. Flagship Pioneering is the manager of VentureLabs VI Manager. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F9: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote1,685,444 Reported balance After 2021-02-08 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2021-02-08 · Purchase · Acquired 71,666 · Balance 1,685,444

F1: On February 8, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 71,666 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering").

F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote2,982,639 Reported balance After 2021-02-08 transaction · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · 2021-02-08 · Purchase · Acquired 71,667 · Balance 2,982,639

F3: On February 8, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 71,667 shares pursuant to the Offering.

F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan serves as sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote738,333 Reported balance After 2021-02-08 transaction · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · 2021-02-08 · Purchase · Acquired 71,667 · Balance 738,333

F5: On February 8, 2021, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") acquired 71,667 shares pursuant to the Offering.

F6: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote42,865 Reported balance Holding disclosure · report date 2021-02-08 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 42,865

F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote2,500,000 Reported balance Holding disclosure · report date 2021-02-08 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 2,500,000

F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship Ventures Fund V, L.P. ("Flagship Fund V") is a member of VentureLabs V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Dr. Afeyan serves as sole manager of Flagship Fund V GP and as sole director of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote2,560,096 Reported balance Holding disclosure · report date 2021-02-08 · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · Balance 2,560,096

F9: Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote639,360 Reported balance Holding disclosure · report date 2021-02-08 · row 7 Holding and transaction disclosures are not merged.
1 source row

Row 7 · Balance 639,360

F10: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote6,560,523 Reported balance Holding disclosure · report date 2021-02-08 · row 8 Holding and transaction disclosures are not merged.
1 source row

Row 8 · Balance 6,560,523

F11: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote216,451 Reported balance Holding disclosure · report date 2021-02-08 · row 9 Holding and transaction disclosures are not merged.
1 source row

Row 9 · Balance 216,451

F12: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Dr. Afeyan is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote1,649,999 Reported balance Holding disclosure · report date 2021-02-08 · row 10 Holding and transaction disclosures are not merged.
1 source row

Row 10 · Balance 1,649,999

F13: Shares held by Cadena LLC ("Cadena"). Dr. Afeyan is the sole manager of Cadena. Each of the reporting persons except for Cadena disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On February 8, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 71,666 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering").

F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F3: On February 8, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 71,667 shares pursuant to the Offering.

F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan serves as sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F5: On February 8, 2021, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") acquired 71,667 shares pursuant to the Offering.

F6: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship Ventures Fund V, L.P. ("Flagship Fund V") is a member of VentureLabs V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Dr. Afeyan serves as sole manager of Flagship Fund V GP and as sole director of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F9: Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F10: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F11: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F12: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Dr. Afeyan is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F13: Shares held by Cadena LLC ("Cadena"). Dr. Afeyan is the sole manager of Cadena. Each of the reporting persons except for Cadena disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Moderna, Inc.

Report date May 21, 2026 · Filed May 22, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Flagship Pioneering, LLC3,924 Last balance in matching sequence After 2026-05-21 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2026-05-21 · Exercise / conversion · Acquired 9,263 · Balance 13,187

F1: On May 21, 2026, Flagship Pioneering, LLC ("Flagship Pioneering") exercised options to purchase 9,263 shares of the Issuer's Common Stock at $19.15 per share, which options were set to expire on August 10, 2026.

F2: The securities are held directly by Flagship Pioneering. Flagship Pioneering is contractually obligated to transfer and/or remit the proceeds of any sale of shares to Flagship Fund IV, L.P. ("Flagship Fund IV"). The reporting person is the ultimate control person of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Row 2 · 2026-05-21 · Sale · Disposed 9,263 · Balance 3,924

F2: The securities are held directly by Flagship Pioneering. Flagship Pioneering is contractually obligated to transfer and/or remit the proceeds of any sale of shares to Flagship Fund IV, L.P. ("Flagship Fund IV"). The reporting person is the ultimate control person of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.15 · Expires 2026-08-10IndirectBy Flagship Pioneering, LLC0 Reported balance After 2026-05-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-05-21 · Exercise / conversion · Disposed 9,263 · Balance 0

F1: On May 21, 2026, Flagship Pioneering, LLC ("Flagship Pioneering") exercised options to purchase 9,263 shares of the Issuer's Common Stock at $19.15 per share, which options were set to expire on August 10, 2026.

F5: The options were fully vested and exercisable.

F2: The securities are held directly by Flagship Pioneering. Flagship Pioneering is contractually obligated to transfer and/or remit the proceeds of any sale of shares to Flagship Fund IV, L.P. ("Flagship Fund IV"). The reporting person is the ultimate control person of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship Ventures Fund IV, L.P.3,880,328 Reported balance Holding disclosure · report date 2026-05-21 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 3,880,328

F3: The securities are held directly by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship Ventures Fund IV-Rx, L.P.747,897 Reported balance Holding disclosure · report date 2026-05-21 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 747,897

F4: The securities are held directly by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect2,224,015 Reported balance Holding disclosure · report date 2026-05-21 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 2,224,015

Filing footnotes · ownership attribution and instrument terms

F1: On May 21, 2026, Flagship Pioneering, LLC ("Flagship Pioneering") exercised options to purchase 9,263 shares of the Issuer's Common Stock at $19.15 per share, which options were set to expire on August 10, 2026.

F2: The securities are held directly by Flagship Pioneering. Flagship Pioneering is contractually obligated to transfer and/or remit the proceeds of any sale of shares to Flagship Fund IV, L.P. ("Flagship Fund IV"). The reporting person is the ultimate control person of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

F3: The securities are held directly by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

F4: The securities are held directly by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

F5: The options were fully vested and exercisable.

Omega Therapeutics, Inc.

Report date June 07, 2023 · Filed June 09, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.39 · Expires 2033-06-06Direct18,118 Reported balance After 2023-06-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-06-07 · Grant · Acquired 18,118 · Balance 18,118

F1: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

Rubius Therapeutics, Inc.

Report date May 12, 2022 · Filed May 13, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2032-05-11Direct25,000 Reported balance After 2022-05-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2022-05-12 · Grant · Acquired 25,000 · Balance 25,000

F1: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service.

Sana Biotechnology, Inc.

Report date February 12, 2024 · Filed February 14, 2024

Jointly reported with Flagship Pioneering, LLC

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Pre-Funded Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00IndirectBy Flagship Pioneering Fund VII, L.P.2,727,272 Reported balance After 2024-02-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-02-12 · Purchase · Acquired 2,727,272 · Balance 2,727,272

F1: On February 12, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired pre-funded warrants to purchase 2,727,272 shares of Common Stock (the "Pre-Funded Warrants") at a purchase price of $5.4999 per Pre-Funded Warrant. The Pre-Funded Warrants do not have an expiration date.

F2: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: On February 12, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired pre-funded warrants to purchase 2,727,272 shares of Common Stock (the "Pre-Funded Warrants") at a purchase price of $5.4999 per Pre-Funded Warrant. The Pre-Funded Warrants do not have an expiration date.

F2: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Nutritional Health LTP Fund, L.P.5,875,711 Reported balance After 2022-07-05 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2022-07-05 · Purchase · Acquired 2,912,748 · Balance 5,875,711

F1: On July 5, 2022, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 2,912,748 shares and 5,825,495 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $3.15 per share.

F2: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship Pioneering Fund VII, L.P.5,825,495 Reported balance After 2022-07-05 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2022-07-05 · Purchase · Acquired 5,825,495 · Balance 5,825,495

F1: On July 5, 2022, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 2,912,748 shares and 5,825,495 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $3.15 per share.

F3: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Dr. Afeyan is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship Ventures Fund IV, L.P.4,434,600 Reported balance Holding disclosure · report date 2022-07-05 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 4,434,600

F4: Shares held by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship Ventures Fund IV-Rx, L.P.1,283,282 Reported balance Holding disclosure · report date 2022-07-05 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 1,283,282

F5: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship Pioneering Fund VI, L.P.2,962,963 Reported balance Holding disclosure · report date 2022-07-05 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 2,962,963

F6: Shares held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering is the manager of Flagship Fund VI GP. Dr. Afeyan is the CEO, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VI disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Flagship VentureLabs IV LLC2,734,994 Reported balance Holding disclosure · report date 2022-07-05 · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · Balance 2,734,994

F7: Shares held by Flagship VentureLabs IV LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Each of the reporting persons except VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Noubar B. Afeyan, Ph.D.376,018 Reported balance Holding disclosure · report date 2022-07-05 · row 7 Holding and transaction disclosures are not merged.
1 source row

Row 7 · Balance 376,018

F8: Shares held by Dr. Afeyan. Each of the reporting persons except for Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Includes 12,853 shares held through a trust for the benefit of Dr. Afeyan's children. Dr. Afeyan disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares for Section 16 or any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: On July 5, 2022, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 2,912,748 shares and 5,825,495 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $3.15 per share.

F2: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F3: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Dr. Afeyan is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F4: Shares held by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F5: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F6: Shares held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering is the manager of Flagship Fund VI GP. Dr. Afeyan is the CEO, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VI disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F7: Shares held by Flagship VentureLabs IV LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Each of the reporting persons except VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F8: Shares held by Dr. Afeyan. Each of the reporting persons except for Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Includes 12,853 shares held through a trust for the benefit of Dr. Afeyan's children. Dr. Afeyan disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares for Section 16 or any other purpose.

Syros Pharmaceuticals, Inc.

Report date December 31, 2017 · Filed February 13, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2017-09-08 transaction · row 1
1 source row

Row 1 · 2017-09-08 · Gift · Disposed 24,527 · Balance 0

Past disclosures · reporting ended (5)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Section 16 reporting ended · disclosed 2016-09-26. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect668,912 Reported balance After 2016-09-22 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2016-09-22 · Sale · Disposed 112,731 · Balance 668,912

F4: The transactions were executed in multiple trades at prices ranging from $3.15 to $3.29. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.

F1: Held by Flagship Ventures Fund IV, L.P. ("Flagship IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship IV LLC") is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons, other than Flagship IV, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect167,288 Reported balance After 2016-09-22 transaction · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · 2016-09-22 · Sale · Disposed 28,163 · Balance 167,288

F4: The transactions were executed in multiple trades at prices ranging from $3.15 to $3.29. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.

F2: Held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx"). Flagship IV LLC is the general partner of Flagship IV Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons, other than Flagship IV-Rx, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect480,545 Reported balance After 2016-09-22 transaction · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · 2016-09-22 · Sale · Disposed 188,367 · Balance 480,545

F5: The transactions were executed in multiple trades at prices ranging from $3.15 to $3.235. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.

F1: Held by Flagship Ventures Fund IV, L.P. ("Flagship IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship IV LLC") is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons, other than Flagship IV, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect120,198 Reported balance After 2016-09-22 transaction · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · 2016-09-22 · Sale · Disposed 47,090 · Balance 120,198

F5: The transactions were executed in multiple trades at prices ranging from $3.15 to $3.235. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.

F2: Held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx"). Flagship IV LLC is the general partner of Flagship IV Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons, other than Flagship IV-Rx, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect468,063 Reported balance After 2016-09-23 transaction · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · 2016-09-23 · Sale · Disposed 12,482 · Balance 468,063

F6: The transactions were executed in multiple trades at prices ranging from $3.15 to $3.16. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.

F1: Held by Flagship Ventures Fund IV, L.P. ("Flagship IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship IV LLC") is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons, other than Flagship IV, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect117,080 Reported balance After 2016-09-23 transaction · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · 2016-09-23 · Sale · Disposed 3,118 · Balance 117,080

F6: The transactions were executed in multiple trades at prices ranging from $3.15 to $3.16. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.

F2: Held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx"). Flagship IV LLC is the general partner of Flagship IV Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons, other than Flagship IV-Rx, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect426,885 Reported balance After 2016-09-23 transaction · row 7 Holding and transaction disclosures are not merged.
1 source row

Row 7 · 2016-09-23 · Sale · Disposed 41,178 · Balance 426,885

F7: The transactions were executed in multiple trades at prices ranging from $3.10 to $3.15. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.

F1: Held by Flagship Ventures Fund IV, L.P. ("Flagship IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship IV LLC") is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons, other than Flagship IV, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect106,787 Reported balance After 2016-09-23 transaction · row 8 Holding and transaction disclosures are not merged.
1 source row

Row 8 · 2016-09-23 · Sale · Disposed 10,293 · Balance 106,787

F7: The transactions were executed in multiple trades at prices ranging from $3.10 to $3.15. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.

F2: Held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx"). Flagship IV LLC is the general partner of Flagship IV Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons, other than Flagship IV-Rx, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect1,833,802 Reported balance Holding disclosure · report date 2016-09-22 · row 9 Holding and transaction disclosures are not merged.
1 source row

Row 9 · Balance 1,833,802

F3: Held by Flagship Ventures Fund 2007, L.P. ("Flagship 2007"). Flagship Ventures 2007 General Partner LLC ("Flagship 2007 LLC") is the general partner of Flagship 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship 2007 LLC. Flagship 2007 LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship 2007. Each of the filing persons, other than Flagship 2007, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Held by Flagship Ventures Fund IV, L.P. ("Flagship IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship IV LLC") is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons, other than Flagship IV, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F2: Held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx"). Flagship IV LLC is the general partner of Flagship IV Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons, other than Flagship IV-Rx, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F3: Held by Flagship Ventures Fund 2007, L.P. ("Flagship 2007"). Flagship Ventures 2007 General Partner LLC ("Flagship 2007 LLC") is the general partner of Flagship 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship 2007 LLC. Flagship 2007 LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship 2007. Each of the filing persons, other than Flagship 2007, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F4: The transactions were executed in multiple trades at prices ranging from $3.15 to $3.29. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.

F5: The transactions were executed in multiple trades at prices ranging from $3.15 to $3.235. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.

F6: The transactions were executed in multiple trades at prices ranging from $3.15 to $3.16. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.

F7: The transactions were executed in multiple trades at prices ranging from $3.10 to $3.15. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.

Denali Therapeutics Inc.

Report date December 12, 2017 · Filed December 12, 2017

Jointly reported with Flagship Ventures Fund V, L.P., Flagship Ventures Fund V General Partner LLC

Section 16 reporting ended · disclosed 2017-12-12. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect8,918,749 Reported balance After 2017-12-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2017-12-12 · Conversion · Acquired 8,606,249 · Balance 8,918,749

F1: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2: The Series A-2 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F3: The Series B-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4: Held by Flagship Ventures Fund V, L.P. ("Flagship V"). Flagship Ventures Fund V General Partner LLC ("Flagship V LLC") is the general partner of Flagship V. Noubar B. Afeyan, Ph.D. is the manager of Flagship V LLC. Flagship V LLC and Dr. Afeyan may be deemed to possess voting and investment control over all shares held by Flagship V. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

Series A-1 Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2017-12-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2017-12-12 · Conversion · Disposed 8,324,999 · Balance 0

F1: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4: Held by Flagship Ventures Fund V, L.P. ("Flagship V"). Flagship Ventures Fund V General Partner LLC ("Flagship V LLC") is the general partner of Flagship V. Noubar B. Afeyan, Ph.D. is the manager of Flagship V LLC. Flagship V LLC and Dr. Afeyan may be deemed to possess voting and investment control over all shares held by Flagship V. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

Series A-2 Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2017-12-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2017-12-12 · Conversion · Disposed 125,000 · Balance 0

F2: The Series A-2 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4: Held by Flagship Ventures Fund V, L.P. ("Flagship V"). Flagship Ventures Fund V General Partner LLC ("Flagship V LLC") is the general partner of Flagship V. Noubar B. Afeyan, Ph.D. is the manager of Flagship V LLC. Flagship V LLC and Dr. Afeyan may be deemed to possess voting and investment control over all shares held by Flagship V. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

Series B-1 Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2017-12-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2017-12-12 · Conversion · Disposed 156,250 · Balance 0

F3: The Series B-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4: Held by Flagship Ventures Fund V, L.P. ("Flagship V"). Flagship Ventures Fund V General Partner LLC ("Flagship V LLC") is the general partner of Flagship V. Noubar B. Afeyan, Ph.D. is the manager of Flagship V LLC. Flagship V LLC and Dr. Afeyan may be deemed to possess voting and investment control over all shares held by Flagship V. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2: The Series A-2 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F3: The Series B-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4: Held by Flagship Ventures Fund V, L.P. ("Flagship V"). Flagship Ventures Fund V General Partner LLC ("Flagship V LLC") is the general partner of Flagship V. Noubar B. Afeyan, Ph.D. is the manager of Flagship V LLC. Flagship V LLC and Dr. Afeyan may be deemed to possess voting and investment control over all shares held by Flagship V. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

Quanterix Corp

Report date December 11, 2017 · Filed December 13, 2017

Jointly reported with Flagship Ventures Fund 2004 L P, Flagship Ventures General Partner LLC, Kania Edwin

Section 16 reporting ended · disclosed 2017-12-13. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,030,495 Last balance in matching sequence After 2017-12-11 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rows

Row 1 · 2017-12-11 · Conversion · Acquired 398,257 · Balance 398,257

F1: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security.

F2: Held by Flagship Ventures Fund 2004, L.P. Flagship Ventures General Partner LLC (the "GP") is the General Partner of Flagship Ventures Fund 2004, L.P. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the Managers of the GP. The GP, Dr. Afeyan and Mr. Kania may be deemed to possess voting and investment control over all shares held by Flagship Ventures Fund 2004, L.P. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

Row 2 · 2017-12-11 · Conversion · Acquired 1,045,426 · Balance 1,443,683

F1: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security.

F2: Held by Flagship Ventures Fund 2004, L.P. Flagship Ventures General Partner LLC (the "GP") is the General Partner of Flagship Ventures Fund 2004, L.P. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the Managers of the GP. The GP, Dr. Afeyan and Mr. Kania may be deemed to possess voting and investment control over all shares held by Flagship Ventures Fund 2004, L.P. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

Row 3 · 2017-12-11 · Conversion · Acquired 477,042 · Balance 1,920,725

F1: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security.

F2: Held by Flagship Ventures Fund 2004, L.P. Flagship Ventures General Partner LLC (the "GP") is the General Partner of Flagship Ventures Fund 2004, L.P. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the Managers of the GP. The GP, Dr. Afeyan and Mr. Kania may be deemed to possess voting and investment control over all shares held by Flagship Ventures Fund 2004, L.P. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

Row 4 · 2017-12-11 · Conversion · Acquired 109,770 · Balance 2,030,495

F1: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security.

F2: Held by Flagship Ventures Fund 2004, L.P. Flagship Ventures General Partner LLC (the "GP") is the General Partner of Flagship Ventures Fund 2004, L.P. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the Managers of the GP. The GP, Dr. Afeyan and Mr. Kania may be deemed to possess voting and investment control over all shares held by Flagship Ventures Fund 2004, L.P. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

Series A-1 Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2017-12-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2017-12-11 · Conversion · Disposed 1,280,000 · Balance 0

F1: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security.

F3: These shares were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, at any time after the issuance of such shares, at the holder's election.

F4: Not applicable.

F2: Held by Flagship Ventures Fund 2004, L.P. Flagship Ventures General Partner LLC (the "GP") is the General Partner of Flagship Ventures Fund 2004, L.P. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the Managers of the GP. The GP, Dr. Afeyan and Mr. Kania may be deemed to possess voting and investment control over all shares held by Flagship Ventures Fund 2004, L.P. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

Series A-2 Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2017-12-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2017-12-11 · Conversion · Disposed 3,360,000 · Balance 0

F1: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security.

F3: These shares were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, at any time after the issuance of such shares, at the holder's election.

F4: Not applicable.

F2: Held by Flagship Ventures Fund 2004, L.P. Flagship Ventures General Partner LLC (the "GP") is the General Partner of Flagship Ventures Fund 2004, L.P. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the Managers of the GP. The GP, Dr. Afeyan and Mr. Kania may be deemed to possess voting and investment control over all shares held by Flagship Ventures Fund 2004, L.P. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

Series B Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2017-12-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2017-12-11 · Conversion · Disposed 1,533,214 · Balance 0

F1: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security.

F3: These shares were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, at any time after the issuance of such shares, at the holder's election.

F4: Not applicable.

F2: Held by Flagship Ventures Fund 2004, L.P. Flagship Ventures General Partner LLC (the "GP") is the General Partner of Flagship Ventures Fund 2004, L.P. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the Managers of the GP. The GP, Dr. Afeyan and Mr. Kania may be deemed to possess voting and investment control over all shares held by Flagship Ventures Fund 2004, L.P. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

Series C Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2017-12-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2017-12-11 · Conversion · Disposed 352,800 · Balance 0

F1: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security.

F3: These shares were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, at any time after the issuance of such shares, at the holder's election.

F4: Not applicable.

F2: Held by Flagship Ventures Fund 2004, L.P. Flagship Ventures General Partner LLC (the "GP") is the General Partner of Flagship Ventures Fund 2004, L.P. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the Managers of the GP. The GP, Dr. Afeyan and Mr. Kania may be deemed to possess voting and investment control over all shares held by Flagship Ventures Fund 2004, L.P. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of preferred stock automatically converted into common stock immediately prior to the closing of the Issuer's initial public offering using a calculation defined in the Issuer's Restated Certificate of Incorporation, as amended, based on the initial purchase price and the conversion rate in effect at the time of conversion. The shares of preferred stock automatically converted on a 1-for-3.214 basis and such conversion rate is reflected in the amount of common stock underlying the security.

F2: Held by Flagship Ventures Fund 2004, L.P. Flagship Ventures General Partner LLC (the "GP") is the General Partner of Flagship Ventures Fund 2004, L.P. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the Managers of the GP. The GP, Dr. Afeyan and Mr. Kania may be deemed to possess voting and investment control over all shares held by Flagship Ventures Fund 2004, L.P. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.

F3: These shares were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, at any time after the issuance of such shares, at the holder's election.

F4: Not applicable.

Section 16 reporting ended · disclosed 2023-08-15. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Flagship Ventures Fund V, L.P.0 Reported balance After 2023-08-11 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2023-08-11 · Other · Disposed 683,760 · Balance 0

F1: Pursuant to the terms of that certain Agreement and Plan of Merger by and among the Issuer, Eli Lilly and Company and Shenandoah Acquisition Corporation, dated as of June 28, 2023, these shares were tendered in exchange for (a) $14.92 per share and (b) one contingent value right per Share (each, a "CVR"), which represents the contractual right to receive up to three contingent payments for an aggregate of up to $111.64 per CVR, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones.

F2: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The share amounts in this Form 4 have been adjusted for the Reverse Split.

F3: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectBy Flagship Pioneering Special Opportunities Fund II, L.P.0 Reported balance After 2023-08-11 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2023-08-11 · Other · Disposed 113,960 · Balance 0

F1: Pursuant to the terms of that certain Agreement and Plan of Merger by and among the Issuer, Eli Lilly and Company and Shenandoah Acquisition Corporation, dated as of June 28, 2023, these shares were tendered in exchange for (a) $14.92 per share and (b) one contingent value right per Share (each, a "CVR"), which represents the contractual right to receive up to three contingent payments for an aggregate of up to $111.64 per CVR, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones.

F2: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The share amounts in this Form 4 have been adjusted for the Reverse Split.

F4: Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Opportunities Fund II GP. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except Flagship Opportunities Fund II disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of that certain Agreement and Plan of Merger by and among the Issuer, Eli Lilly and Company and Shenandoah Acquisition Corporation, dated as of June 28, 2023, these shares were tendered in exchange for (a) $14.92 per share and (b) one contingent value right per Share (each, a "CVR"), which represents the contractual right to receive up to three contingent payments for an aggregate of up to $111.64 per CVR, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones.

F2: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The share amounts in this Form 4 have been adjusted for the Reverse Split.

F3: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F4: Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Opportunities Fund II GP. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except Flagship Opportunities Fund II disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

Section 16 reporting ended · disclosed 2019-10-31. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2019-10-29 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2019-10-29 · Other · Disposed 1,469,173 · Balance 0

F1: On October 29, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP"), pro rata and without consideration, 1,469,173 shares of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 61,537 shares it received from Flagship Fund IV. Noubar B. Afeyan, Ph.D., a manager of Flagship Fund IV GP, received 27,799 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is a manager of Flagship Fund IV GP and, for purposes of Flagship Fund IV's investment in the Issuer, Dr. Afeyan may be deemed to have voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein..

Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2019-10-29 transaction · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · 2019-10-29 · Other · Disposed 1,061,102 · Balance 0

F3: On October 29, 2019, Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007") distributed to its limited partners and sole general partner, Flagship Ventures 2007 General Partner LLC ("Flagship Fund 2007 GP"), pro rata and without consideration, 1,061,102 shares of the Issuer's common stock. Flagship Fund 2007 GP, in turn, distributed to its members, pro rata and without consideration, the 248,379 shares it received from Flagship Fund 2007. Dr. Afeyan, a manager of Flagship Fund 2007 GP, received 92,796 shares through Flagship Fund 2007 GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F4: Shares held by Flagship Fund 2007. Flagship Fund 2007 GP is the general partner of Flagship Fund 2007. Dr. Afeyan is a manager of Flagship Fund 2007 GP and, for purposes of Flagship Fund 2007's investment in the Issuer, Dr. Afeyan may be deemed to have voting and investment power with respect to all shares held by Flagship Fund 2007. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2019-10-29 transaction · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · 2019-10-29 · Other · Disposed 61,537 · Balance 0

F1: On October 29, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP"), pro rata and without consideration, 1,469,173 shares of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 61,537 shares it received from Flagship Fund IV. Noubar B. Afeyan, Ph.D., a manager of Flagship Fund IV GP, received 27,799 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F5: Held by Flagship Fund IV GP. Each of the filing persons other than Flagship Fund IV GP disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2019-10-29 transaction · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · 2019-10-29 · Other · Disposed 248,379 · Balance 0

F3: On October 29, 2019, Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007") distributed to its limited partners and sole general partner, Flagship Ventures 2007 General Partner LLC ("Flagship Fund 2007 GP"), pro rata and without consideration, 1,061,102 shares of the Issuer's common stock. Flagship Fund 2007 GP, in turn, distributed to its members, pro rata and without consideration, the 248,379 shares it received from Flagship Fund 2007. Dr. Afeyan, a manager of Flagship Fund 2007 GP, received 92,796 shares through Flagship Fund 2007 GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F6: Held by Flagship Fund 2007 GP. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote120,595 Reported balance Holding disclosure · report date 2019-10-29 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 120,595

F1: On October 29, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP"), pro rata and without consideration, 1,469,173 shares of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 61,537 shares it received from Flagship Fund IV. Noubar B. Afeyan, Ph.D., a manager of Flagship Fund IV GP, received 27,799 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F3: On October 29, 2019, Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007") distributed to its limited partners and sole general partner, Flagship Ventures 2007 General Partner LLC ("Flagship Fund 2007 GP"), pro rata and without consideration, 1,061,102 shares of the Issuer's common stock. Flagship Fund 2007 GP, in turn, distributed to its members, pro rata and without consideration, the 248,379 shares it received from Flagship Fund 2007. Dr. Afeyan, a manager of Flagship Fund 2007 GP, received 92,796 shares through Flagship Fund 2007 GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F7: Held by Dr. Afeyan. Each of the filing persons other than Dr. Afeyan disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On October 29, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP"), pro rata and without consideration, 1,469,173 shares of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 61,537 shares it received from Flagship Fund IV. Noubar B. Afeyan, Ph.D., a manager of Flagship Fund IV GP, received 27,799 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is a manager of Flagship Fund IV GP and, for purposes of Flagship Fund IV's investment in the Issuer, Dr. Afeyan may be deemed to have voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein..

F3: On October 29, 2019, Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007") distributed to its limited partners and sole general partner, Flagship Ventures 2007 General Partner LLC ("Flagship Fund 2007 GP"), pro rata and without consideration, 1,061,102 shares of the Issuer's common stock. Flagship Fund 2007 GP, in turn, distributed to its members, pro rata and without consideration, the 248,379 shares it received from Flagship Fund 2007. Dr. Afeyan, a manager of Flagship Fund 2007 GP, received 92,796 shares through Flagship Fund 2007 GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F4: Shares held by Flagship Fund 2007. Flagship Fund 2007 GP is the general partner of Flagship Fund 2007. Dr. Afeyan is a manager of Flagship Fund 2007 GP and, for purposes of Flagship Fund 2007's investment in the Issuer, Dr. Afeyan may be deemed to have voting and investment power with respect to all shares held by Flagship Fund 2007. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein.

F5: Held by Flagship Fund IV GP. Each of the filing persons other than Flagship Fund IV GP disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein.

F6: Held by Flagship Fund 2007 GP. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein.

F7: Held by Dr. Afeyan. Each of the filing persons other than Dr. Afeyan disclaims beneficial ownership of the shares except to the extent, if any, of his or its pecuniary interest therein.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 31, 2024 Filed Aug 2, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 3,428 $120.88 $414,377.33
Disclosure

SEC source: 0000950170-24-090211 · ownership.xml · nonDerivative · entry 3

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,225,324

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.40 to $121.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 31, 2024 Filed Aug 2, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 5,664 $119.84 $678,753.94
Disclosure

SEC source: 0000950170-24-090211 · ownership.xml · nonDerivative · entry 2

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,228,752

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.40 to $120.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 31, 2024 Filed Aug 2, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 4,599 $118.96 $547,107.16
Disclosure

SEC source: 0000950170-24-090211 · ownership.xml · nonDerivative · entry 1

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,234,416

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.38 to $119.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 24, 2024 Filed Jul 26, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 2,000 $119.01 $238,026.00
Disclosure

SEC source: 0000950170-24-087026 · ownership.xml · nonDerivative · entry 4

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,239,015

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.78 to $119.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 24, 2024 Filed Jul 26, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 6,832 $118.30 $808,207.84
Disclosure

SEC source: 0000950170-24-087026 · ownership.xml · nonDerivative · entry 3

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,241,015

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.78 to $118.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 24, 2024 Filed Jul 26, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 3,500 $117.25 $410,376.40
Disclosure

SEC source: 0000950170-24-087026 · ownership.xml · nonDerivative · entry 2

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,247,847

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.73 to $117.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 24, 2024 Filed Jul 26, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 2,668 $116.33 $310,361.77
Disclosure

SEC source: 0000950170-24-087026 · ownership.xml · nonDerivative · entry 1

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,251,347

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.72 to $116.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 17, 2024 Filed Jul 19, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 700 $124.61 $87,230.01
Disclosure

SEC source: 0000950170-24-085011 · ownership.xml · nonDerivative · entry 5

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,254,015

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.48 to $124.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 17, 2024 Filed Jul 19, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 6,699 $123.82 $829,478.22
Disclosure

SEC source: 0000950170-24-085011 · ownership.xml · nonDerivative · entry 4

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,254,715

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.34 to $124.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 17, 2024 Filed Jul 19, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 2,900 $122.86 $356,298.06
Disclosure

SEC source: 0000950170-24-085011 · ownership.xml · nonDerivative · entry 3

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,261,414

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.32 to $123.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 17, 2024 Filed Jul 19, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 2,100 $121.57 $255,296.79
Disclosure

SEC source: 0000950170-24-085011 · ownership.xml · nonDerivative · entry 2

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,264,314

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.24 to $122.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 17, 2024 Filed Jul 19, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 2,601 $120.86 $314,347.50
Disclosure

SEC source: 0000950170-24-085011 · ownership.xml · nonDerivative · entry 1

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,266,414

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.22 to $121.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 10, 2024 Filed Jul 12, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 500 $119.95 $59,976.00
Disclosure

SEC source: 0000950170-24-083327 · ownership.xml · nonDerivative · entry 5

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,269,015

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.73 to $120.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 10, 2024 Filed Jul 12, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 1,100 $119.28 $131,211.19
Disclosure

SEC source: 0000950170-24-083327 · ownership.xml · nonDerivative · entry 4

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,269,515

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.71 to $119.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 10, 2024 Filed Jul 12, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 3,000 $117.83 $353,482.80
Disclosure

SEC source: 0000950170-24-083327 · ownership.xml · nonDerivative · entry 3

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,270,615

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.51 to $118.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 10, 2024 Filed Jul 12, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 4,279 $117.18 $501,418.35
Disclosure

SEC source: 0000950170-24-083327 · ownership.xml · nonDerivative · entry 2

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,273,615

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.51 to $117.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 10, 2024 Filed Jul 12, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 6,121 $116.01 $710,088.64
Disclosure

SEC source: 0000950170-24-083327 · ownership.xml · nonDerivative · entry 1

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,277,894

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.51 to $116.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 26, 2024 Filed Jun 28, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 100 $134.05 $13,405.00
Disclosure

SEC source: 0000950170-24-079172 · ownership.xml · nonDerivative · entry 10

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,284,015

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

Read SEC document
June 26, 2024 Filed Jun 28, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 700 $131.56 $92,088.99
Disclosure

SEC source: 0000950170-24-079172 · ownership.xml · nonDerivative · entry 9

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,284,115

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.33 to $132.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 26, 2024 Filed Jun 28, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 2,705 $130.76 $353,694.98
Disclosure

SEC source: 0000950170-24-079172 · ownership.xml · nonDerivative · entry 8

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,284,815

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.32 to $131.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 26, 2024 Filed Jun 28, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 2,300 $129.84 $298,631.31
Disclosure

SEC source: 0000950170-24-079172 · ownership.xml · nonDerivative · entry 7

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,287,520

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.27 to $130.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 26, 2024 Filed Jun 28, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 1,435 $128.78 $184,797.72
Disclosure

SEC source: 0000950170-24-079172 · ownership.xml · nonDerivative · entry 6

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,289,820

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.26 to $129.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 26, 2024 Filed Jun 28, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 1,100 $127.50 $140,253.85
Disclosure

SEC source: 0000950170-24-079172 · ownership.xml · nonDerivative · entry 5

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,291,255

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.06 to $128.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 26, 2024 Filed Jun 28, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 1,100 $125.71 $138,277.04
Disclosure

SEC source: 0000950170-24-079172 · ownership.xml · nonDerivative · entry 4

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,292,355

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.40 to $126.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 26, 2024 Filed Jun 28, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 1,500 $124.90 $187,352.25
Disclosure

SEC source: 0000950170-24-079172 · ownership.xml · nonDerivative · entry 3

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,293,455

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.30 to $125.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 26, 2024 Filed Jun 28, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 1,600 $123.74 $197,978.08
Disclosure

SEC source: 0000950170-24-079172 · ownership.xml · nonDerivative · entry 2

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,294,955

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.28 to $124.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 26, 2024 Filed Jun 28, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 2,460 $122.69 $301,814.20
Disclosure

SEC source: 0000950170-24-079172 · ownership.xml · nonDerivative · entry 1

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,296,555

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.27 to $123.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 18, 2024 Filed Jun 21, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 100 $136.92 $13,692.00
Disclosure

SEC source: 0000950170-24-076419 · ownership.xml · nonDerivative · entry 5

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,299,015

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

Read SEC document
June 18, 2024 Filed Jun 21, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 200 $135.02 $27,003.00
Disclosure

SEC source: 0000950170-24-076419 · ownership.xml · nonDerivative · entry 4

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,299,115

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 18, 2024 Filed Jun 21, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 6,840 $134.09 $917,197.49
Disclosure

SEC source: 0000950170-24-076419 · ownership.xml · nonDerivative · entry 3

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,299,315

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.74 to $134.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 18, 2024 Filed Jun 21, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 6,160 $133.26 $820,887.14
Disclosure

SEC source: 0000950170-24-076419 · ownership.xml · nonDerivative · entry 2

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,306,155

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.74 to $133.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 18, 2024 Filed Jun 21, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 1,700 $132.22 $224,781.65
Disclosure

SEC source: 0000950170-24-076419 · ownership.xml · nonDerivative · entry 1

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,312,315

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.71 to $132.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 12, 2024 Filed Jun 14, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 200 $150.24 $30,048.00
Disclosure

SEC source: 0000950170-24-073912 · ownership.xml · nonDerivative · entry 8

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,314,015

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.21 to $150.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 12, 2024 Filed Jun 14, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 1,400 $149.39 $209,149.78
Disclosure

SEC source: 0000950170-24-073912 · ownership.xml · nonDerivative · entry 7

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,314,215

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.15 to $149.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 12, 2024 Filed Jun 14, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 1,601 $148.61 $237,929.41
Disclosure

SEC source: 0000950170-24-073912 · ownership.xml · nonDerivative · entry 6

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,315,615

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.08 to $149.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 12, 2024 Filed Jun 14, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 6,397 $147.55 $943,876.07
Disclosure

SEC source: 0000950170-24-073912 · ownership.xml · nonDerivative · entry 5

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,317,216

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.05 to $148.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 12, 2024 Filed Jun 14, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 3,031 $146.55 $444,187.90
Disclosure

SEC source: 0000950170-24-073912 · ownership.xml · nonDerivative · entry 4

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,323,613

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.04 to $147.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 12, 2024 Filed Jun 14, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 1,263 $145.57 $183,860.97
Disclosure

SEC source: 0000950170-24-073912 · ownership.xml · nonDerivative · entry 3

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,326,644

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.04 to $146.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 12, 2024 Filed Jun 14, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 408 $144.46 $58,940.46
Disclosure

SEC source: 0000950170-24-073912 · ownership.xml · nonDerivative · entry 2

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,327,907

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.04 to $145.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 12, 2024 Filed Jun 14, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 700 $142.97 $100,078.72
Disclosure

SEC source: 0000950170-24-073912 · ownership.xml · nonDerivative · entry 1

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,328,315

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.49 to $143.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · balance_after: Includes shares received in distributions-in-kind from Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") made prior to the filing of this report in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

Read SEC document
June 11, 2024 Filed Jun 11, 2024 23:01 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 1,232 $149.40 $184,065.48
Disclosure

SEC source: 0000950170-24-072122 · ownership.xml · nonDerivative · entry 4

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship Ventures Fund IV-Rx, L.P.

Disclosed balance after: 1,528,557

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.00 to $149.755, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: The shares are held directly by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
June 11, 2024 Filed Jun 11, 2024 23:01 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 6,420 $149.40 $959,172.40
Disclosure

SEC source: 0000950170-24-072122 · ownership.xml · nonDerivative · entry 3

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship Ventures Fund IV, L.P.

Disclosed balance after: 7,930,725

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.00 to $149.755, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The shares are held directly by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
June 11, 2024 Filed Jun 11, 2024 23:01 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 31,531 $148.29 $4,675,870.73
Disclosure

SEC source: 0000950170-24-072122 · ownership.xml · nonDerivative · entry 2

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship Ventures Fund IV-Rx, L.P.

Disclosed balance after: 1,529,789

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.00 to $148.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: The shares are held directly by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
June 11, 2024 Filed Jun 11, 2024 23:01 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 163,649 $148.29 $24,268,230.27
Disclosure

SEC source: 0000950170-24-072122 · ownership.xml · nonDerivative · entry 1

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship Ventures Fund IV, L.P.

Disclosed balance after: 7,937,145

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.00 to $148.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The shares are held directly by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
June 05, 2024 Filed Jun 7, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 1,721 $154.86 $266,510.10
Disclosure

SEC source: 0000950170-24-070980 · ownership.xml · nonDerivative · entry 9

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,946,931

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.47 to $155.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 05, 2024 Filed Jun 7, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 400 $153.71 $61,484.00
Disclosure

SEC source: 0000950170-24-070980 · ownership.xml · nonDerivative · entry 8

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,948,652

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.46 to $154.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 05, 2024 Filed Jun 7, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 2,437 $152.90 $372,606.09
Disclosure

SEC source: 0000950170-24-070980 · ownership.xml · nonDerivative · entry 7

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,949,052

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.46 to $153.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 05, 2024 Filed Jun 7, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 3,902 $151.76 $592,172.20
Disclosure

SEC source: 0000950170-24-070980 · ownership.xml · nonDerivative · entry 6

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,951,489

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.37 to $152.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 05, 2024 Filed Jun 7, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 2,840 $151.07 $429,032.84
Disclosure

SEC source: 0000950170-24-070980 · ownership.xml · nonDerivative · entry 5

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,955,391

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.37 to $151.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 05, 2024 Filed Jun 7, 2024 23:00 UTC Moderna, Inc. MRNA · Entity 2025 SaleCommon Stock 300 $149.35 $44,805.00
Disclosure

SEC source: 0000950170-24-070980 · ownership.xml · nonDerivative · entry 4

AFEYAN NOUBAR · CIK 0001222012 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,958,231

F1 · kind: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023, as amended on November 7, 2023.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.32 to $149.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.